Adverse drug reaction active surveillance: Developing a national network in Canada's children's hospitals

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 8, 2009, Pages 713-721

  Carleton, B C ^a   Poole, R L ^b   Smith, M A ^a   Leeder, J S ^c   Ghannadan, R ^a   Ross, C J D ^a   Phillips, M S ^d   Hayden, M R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Adverse drug reaction; Children; Pharmacogenomics; Surveillance

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CODEINE; ANTINEOPLASTIC ANTIBIOTIC; NARCOTIC ANALGESIC AGENT;

ARTICLE; CANADA; CARDIOTOXICITY; CASE CONTROL STUDY; CHILD HEALTH CARE; CONTROLLED STUDY; DRUG FATALITY; DRUG SURVEILLANCE PROGRAM; HEARING IMPAIRMENT; HUMAN; INFANT; INFANT MORTALITY; MAJOR CLINICAL STUDY; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; BREAST FEEDING; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; FEMALE; GENETIC MARKER; GENETICS; HEARING LOSS; HEART DISEASE; HOSPITAL; INTOXICATION; MORTALITY; MULTICENTER STUDY; NEWBORN; ORGANIZATION AND MANAGEMENT; PHARMACOGENETICS; PRESCHOOL CHILD; PROGRAM DEVELOPMENT; PUBLIC HEALTH; TIME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANALGESICS, OPIOID; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BREAST FEEDING; CANADA; CASE-CONTROL STUDIES; CHILD; CHILD HEALTH SERVICES; CHILD, PRESCHOOL; CISPLATIN; CODEINE; FEMALE; GENETIC MARKERS; HEARING LOSS; HEART DISEASES; HOSPITALS, PEDIATRIC; HUMANS; INFANT; INFANT, NEWBORN; NATIONAL HEALTH PROGRAMS; OVERDOSE; PHARMACOGENETICS; PROGRAM DEVELOPMENT; TIME FACTORS;

EID: 70349781292     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1772     Document Type: Article

References (30)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279(15): 1200-1205. (Pubitemid 28193431)
2. White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics 1999; 15(5): 445-458. (Pubitemid 29210948)
3. Philips K. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 2003; 4(3): 231-239.
4. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001; 41(2): 192-199.
5. Fletcher A. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med 1991; 84(6): 341-344.
6. Mittman N, Knowles S, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions. Drug Saf 2004; 27(7): 477-487.
7. Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008; 64(8): 743-752.
8. Review of Food and Drug Administration's Handling of Adverse Drug Reaction Reports. Report No.: A-15-98-50001, Office of the Inspector General, Department of Human and Health Services, 14 December 1999.
9. Gonzalez-Martin G, Caroca CM, Paris E. Adverse drug reactions (ADRs) in hospitalized pediatric patients. A prospective study. Int J Clin Pharmacol Ther 1998; 36(10): 530-533. (Pubitemid 28468228)
10. Martinez-Mir I, Garcia-Lopez M, Palop V, et al. A prospective study of adverse drug reactions in hospitalized children. Br J Clin Pharmacol 1999; 47(6): 681-688. (Pubitemid 29257667)
11. Leeder JS. Developmental and pediatric pharmacogenomics. Pharmacogenomics 2003; 4(3): 331-341.
12. Kearns GK, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action and therapy in infants and children. N Engl J Med 2003; 349(12): 1157-1167.
13. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277(4): 301-306.
14. Impicciatore M. Pharmacogenomic can give children safer medicines. Arch Dis Child 2003; 88(4): 366. (Pubitemid 36398989)
15. Jaja C. Foretelling our pharmacogenomic future. Nat Biotechnol 2003; 21(5): 487-488.
16. Rothstein M. Pharmacogenomics: Social, Ethical, and Clinical Dimensions. John Wiley and Sons, Inc: Hoboken, New Jersey, 2003.
17. Kling J. US FDA contemplates collection of pharmacogenomic data. Nat Biotechnol 2003; 21(6): 590.
18. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8(4): 283-289. (Pubitemid 28372321)
19. Slone Epidemiology Center. Patterns of medication use in the United States: a report from the Slone survey. Boston, MA, 2006. http://www. bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2006.pdf [Accessed 21 November 2007].
20. Health Canada. Important safety information on tylenol with codeine in nursing mothers and ultra-rapid metabolizers of codeine. Health Canada, Ottawa, October 2008. http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/medeff/ tylenol-codeine-hpc-cps-eng.pdf [Accessed 2 December 2008].
21. Food and Drug Administration. Warning on codeine use by nursing mothers. FDA, Rockville, August 2007; http://www.fda.gov/bbs/topics/ NEWS/2007/NEW01685. html [Accessed 27 February 2008].
22. Food and Drug Administration. 2007 Safety alerts for drugs, biologics, medical devices and dietary supplements. FDA, Rockville, 2007; http://www.fda.gov/medwatch/safety/2007/safety07.htm [Accessed 7 December 2007].
23. Food and Drug Administration. FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events. FDA, Rockville, February 2007. http://www.fda.gov/ bbs/topics/news/2007/ new01568.html [Accessed 6 December 2007].
24. Long RM. Planning for a national effort to enable and accelerate discoveries in pharmacogenetics: the NIH pharmacogenetics research network. Clin Pharmacol Ther 2007; 81(3): 450-454.
25. Carleton BC, Poole RL, Milton J, et al. The pediatric adverse drug reaction reporting system. J Pediatr Pharm Pract 1999; 4(6): 284-307.
26. Carleton BC, Lesko A, Milton J, Poole RL. Active surveillance systems for pediatric adverse drug reactions: an idea whose time has come. Curr Ther Res 2001; 62(10): 738-742. (Pubitemid 33097457)
27. Naranjo CA, Busto I, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-245.
28. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother [case report]. Lancet 2006; 368(9536): 704. (Pubitemid 44223697)
29. Madadi P, Koren G, Cairns J, et al. Maternal codeine is not safe for all breast-fed infants. Can Pharm J 2006; 139(6): 56-558. (Pubitemid 46232246)
30. Madadi P, Ross CJD, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85(1): 31-35.